Skip to Content

'
William G. Wierda, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1993 University of Health Sciences/The Chicago Medical School, North Chicago, IL, MD
1992 University of Health Sciences/The Chicago Medical School, North Chicago, IL, PHD, Microbiology and Immunology
1986 University of California, Riverside, CA, BS, Biochemistry

Experience/Service

Academic Appointments

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2012

Administrative Appointments/Responsibilities

Center Medical Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabham S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell C, Osterborg A. Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine-and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab. Clin Lymphoma Myeloma 9(6):E36, 12/2009. PMID: 19951868.
2. Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 115(17):3830-41, 9/1/2009. e-Pub 6/2009. PMID: 19536902.
3. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M.. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 4/1/2009. e-Pub 2/17/2009. PMID: 19224852.
4. Wierda W. New prognostic factors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7(1):32-42, 1/2009. PMID: 19274038.
5. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-1939, 10/2007. PMID: 17917961.
6. Wierda W, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do K-A, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M.. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 6/1/2007. e-Pub 2/13/2007. PMID: 17299097.
7. Wierda WG, Kipps J. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 20(3):557-68, 2007.
8. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 1/2006. PMID: 16353201.
9. Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10; quiz 11-2, 8/2005. PMID: 16201050.
10. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-4078, 6/20/2005. e-Pub 3/14/2005. PMID: 15767647.
11. Motta M, Rassenti L, Shelvin B, Lerner S, Kipps T, Keating M, Wierda W. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B cell chronic lymphocytic leukemia. Leukemia 19:1788-1793, 2005.
12. Wierda WG, Keating MJ, O’Brien S. Refractory chronic lymphocytic leukemia – prognosis and treatment options. Am J Cancer 3(3):163-178, 2004.

Abstracts

1. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Strange M, Nielsen TG, Russell CA. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood 114(22):90 (#207), 11/2009.

Grant & Contract Support

Title: Cellular Therapy for CLL Utilizing Chimeric Antigen Receptors (CARs)
Funding Source: CLL Global Research Foundation
Role: Principal Investigator
Duration: 1/1/2013 - 12/31/2013
 
Title: Chronic Lymphocytic Leukemia Research Consortium Core D
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Thomas Kipps, M.D., UCSD
Duration: 9/24/2012 - 8/31/2017
 
Title: Chronic Lymphocytic Leukemia Research Consortium Core D multi
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Thomas Kipps, M.D., UCSD
Duration: 9/24/2012 - 8/31/2017
 
Title: Phase 1 study of 8-Cl-adenosine in CLL. Protocol 2004-0144.
Funding Source: Food and Drug Administration (FDA)
Role: Co-Investigator
Principal Investigator: Varsha Gandhi, PhD
Duration: 11/1/2008 - 10/31/2013

Last updated: 3/12/2013